Hepatocellular carcinoma
Hepatocellular carcinoma
复制标题
DOI：
10.1007/s00104-022-01661-4
复制
发表时间：
2022-07-01
期刊：
影响因子：
--
通讯作者：
Linecker, Michael
中科院分区：
文献类型：
--
作者：
Braun, Felix;Schaefer, Jost Philipp;Linecker, Michael
在过去的十年中，肝细胞癌在肝硬变的治疗范围已经扩大，包括外科、介入和全身治疗。肿瘤分期和肝功能对治疗策略有重要影响。治疗可以通过肝切除或移植来实现。器官短缺和等待时间限制了接受移植的机会。局部治疗可以作为移植的桥梁，或在新辅助环境下缩小规模，也可以用作姑息治疗。晚期患者可能受益于全身或免疫治疗。现代多模式治疗计划、时间安排和重新评估是专门研究肝脏的肿瘤委员会的任务的一部分，包括肝脏移植的选择。治疗方法可以单独使用，也可以根据中心的经验联合使用。治疗策略应始终在最初表现时进行。
The therapeutic spectrum of hepatocellular carcinoma (HCC) in cirrhosis has expanded over the last decade and consists of surgical, interventional and systemic approaches. The tumor stage and liver function are important for the therapeutic strategy. Curation can be achieved by liver resection or transplantation. Access to transplantation is limited by organ shortage and waiting time. Locoregional therapies can be used as a bridge to transplant or for down-sizing in a neoadjuvant setting as well as palliative therapy. Advanced stages might benefit from systemic or immunotherapy. Modern multimodal therapy planning, timing and reevaluation are part of the tasks of tumor boards specialised in the liver, including the option of liver transplantation. Therapies can be used alone or in combination and according to the experience of the center. A curative strategy should always be pursued at initial presentation.